1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Delayed London Stock Exchange  -  11:39 2022-07-01 am EDT
10722.00 GBX   -0.72%
04:08pSECTOR UPDATE : Health Care Stocks Rebound Late
02:08pSECTOR UPDATE : Health Care Stocks Struggling for Direction
12:04pAstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

From storage to transport, hurdles to getting COVID vaccine to N.Koreans

05/18/2022 | 03:01am EDT
FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease in Pyongyang, North Korea

SEOUL (Reuters) - As North Korea battles its first known COVID outbreak, a lack of storage, chronic power shortages and inadequately trained medical staff pose acute challenges to inoculating its 25 million people - even with outside help, analysts said.

North Korea has not responded to offers of aid from South Korea and international vaccine-sharing programmes, but prefers U.S.-made Moderna and Pfizer over China's Sinovac or British-Swedish Astrazeneca shots, according to South Korean officials.

Both the U.S. vaccines rely on technology known as mRNA, and require super-cold storage. Sinovac or AstraZeneca vaccines can be transported and stored at normal refrigerator temperatures.

"Moderna and Pfizer vaccines require a low-temperature storage system, which North Korea does not have," said Moon Jin-soo, director of the Institute for Health and Unification Studies at Seoul National University. "It would require a ton of additional materials to use them for inoculation."

South Korean officials have said it is not clear whether the North has access to such storage systems.

In March, the U.N. Security Council gave a sanctions exemption to the UNICEF to ship such "cold-chain" equipment to North Korea to assist with vaccinations.

The items included three walk-in cold rooms for "storage of routine immunization vaccines," though it was not immediately confirmed whether they had been shipped amid strict border restrictions.

According to the North's latest Voluntary National Review report presented to the U.N. last year, only 34.6% of its population had access to electricity, and the country's roads and railways were, "in general, not in standard condition."

Given those conditions, only few cities could accommodate the cold storage units, experts said.

Whether North Korea can mobilise trained medical personnel on a large scale for a nationwide inoculation campaign also remains an open question.

"You need a system and trained medical experts to distribute the doses and inject the shots. I doubt the North has that," said Jacob Lee, a professor of infectious diseases at South Korea's Hallym University School of Medicine.

North Korea has inoculated children for diseases such as tuberculosis with the help of international organizations. But U.N. aid agencies and most other relief groups have pulled out of the country amid extended border shutdowns.

South Korea's foreign minister, Park Jin, said on Tuesday he would ask Washington for sanctions exemptions to send needed equipment to the North if it asks.

"The most important thing is speed," said Shin Young-jeon, a professor at Hanyang University's College of Medicine in Seoul. "The virus is already spreading fast, and without swift vaccination and immunity building, the death toll could soar to an uncontrollable level."

(Reporting by Soo-hyang Choi. Editing by Gerry Doyle)

By Soo-hyang Choi

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.72% 10722 Delayed Quote.24.38%
MODERNA, INC. 4.97% 149.95 Delayed Quote.-43.76%
PFIZER, INC. -0.23% 52.31 Delayed Quote.-13.73%
All news about ASTRAZENECA PLC
04:08pSECTOR UPDATE : Health Care Stocks Rebound Late
02:08pSECTOR UPDATE : Health Care Stocks Struggling for Direction
12:04pAstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials
09:03aAstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combination..
07:55aAstraZeneca Enters New 3-Year Agreement with Oxford Biomedica
06:56aNew chronic kidney disease (CKD) study indicates that CKD is present in one out of ten ..
06:55aImfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN..
03:32aPharmaceutical companies still have the upper hand
02:57aOxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility
02:54aOxford Biomedica signs new deal to make AstraZeneca COVID shot
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 717 M - -
Net income 2022 4 956 M - -
Net Debt 2022 24 403 M - -
P/E ratio 2022 40,5x
Yield 2022 2,26%
Capitalization 202 B 200 B -
EV / Sales 2022 5,19x
EV / Sales 2023 4,77x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 131,24 $
Average target price 142,76 $
Spread / Average Target 8,78%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC24.38%203 345
JOHNSON & JOHNSON3.46%467 100
PFIZER, INC.-13.73%294 179
ROCHE HOLDING AG-15.97%272 586
ABBVIE INC.13.12%270 651